The firm has acquired the US rights for Antara (Fenofibrate capsules in the strength of 43 mg and 130 mg) on September 25, under the procedure of US bankruptcy court.
Earlier, Lupin had filed an Abbreviated New Drug Application for Fenofibrate capsules of the same composition.
On September 21, 2009, prior to the acquisition of Antara, Lupin sold its ANDA to Dr Reddy's Laboratories. Lupin also settled and resolved the pending litigation regarding the ANDA product, the filing said.
Acquisition of Anatara would enable Lupin to enter the primary care market with a three-product portfolio. The two other products are Suprax, used for treating bacterial infections, and Allernaze, prescribed for various allergies.
The filing noted that the firm would be more than doubling its sales force size in the next 12 months to reach key targets for these products.
Lupin rejigs R&D plan, to foray into biotech
Meet the cutie in Aap Ki Antara
Patents: Nestle,Takeda sue Lupin, Torrent
Pfizer sues Sun, Wockhardt, Lupin in US